PARP Inhibitors as Monotherapy in Daily Practice for Advanced Prostate Cancers

Area of Science:

• Oncology
• Genetics
• Pharmacology

Background:

• Metastatic castration-resistant prostate cancer (mCRPC) remains a lethal disease despite survival improvements.
• Homologous recombination repair (HRR) gene alterations are linked to poor prognosis in mCRPC.
• Poly-ADP-ribose polymerase (PARP) inhibitors (PARPis) exploit synthetic lethality in HRR-deficient tumors.

Purpose of the Study:

• To review the rationale and outcomes of PARPi treatment in mCRPC.
• To provide a pragmatic approach to PARPi prescription and patient selection.
• To highlight the role of molecular screening and genetic counseling.

Main Methods:

• Review of existing literature on PARPi efficacy in mCRPC.
• Analysis of patient selection criteria based on HRR gene alterations.
• Discussion of clinical implementation challenges and genetic counseling implications.

Main Results:

• PARPis demonstrate anti-tumoral effects in mCRPC patients with HRR alterations, particularly BRCA2 mutations.
• Olaparib and rucaparib are approved but present challenges in clinical application.
• Molecular screening is crucial for identifying eligible patients.

Conclusions:

• PARPi therapy offers a targeted approach for a subset of mCRPC patients.
• Standardizing patient selection and prescription protocols is essential for optimal use.
• Integrating molecular screening and genetic counseling can improve treatment outcomes.